Patterson Companies (PDCO) to Release Quarterly Earnings on Wednesday

Patterson Companies (NASDAQ:PDCO - Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.62 per share and revenue of $1.63 billion for the quarter. Patterson Companies has set its FY25 guidance at $2.25-$2.35 EPS and its FY 2025 guidance at 2.250-2.350 EPS.

Patterson Companies (NASDAQ:PDCO - Get Free Report) last issued its quarterly earnings results on Thursday, December 5th. The company reported $0.47 EPS for the quarter, missing analysts' consensus estimates of $0.49 by ($0.02). The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.65 billion. Patterson Companies had a return on equity of 19.77% and a net margin of 2.37%. The business's revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.50 EPS. On average, analysts expect Patterson Companies to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Patterson Companies Stock Performance

Shares of PDCO stock traded up $0.01 on Friday, hitting $31.07. The company had a trading volume of 707,171 shares, compared to its average volume of 1,269,096. The firm has a market cap of $2.74 billion, a P/E ratio of 18.17, a price-to-earnings-growth ratio of 2.70 and a beta of 0.90. The company has a 50-day moving average price of $30.93 and a 200-day moving average price of $25.15. The company has a quick ratio of 0.76, a current ratio of 1.37 and a debt-to-equity ratio of 0.34. Patterson Companies has a twelve month low of $19.45 and a twelve month high of $31.79.

Wall Street Analyst Weigh In

PDCO has been the subject of several analyst reports. StockNews.com initiated coverage on Patterson Companies in a report on Saturday, February 15th. They issued a "hold" rating for the company. Morgan Stanley lifted their price target on Patterson Companies from $27.00 to $31.35 and gave the company an "equal weight" rating in a research note on Tuesday, December 17th. Mizuho started coverage on Patterson Companies in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $23.00 price target for the company. Piper Sandler cut their price target on Patterson Companies from $26.00 to $24.00 and set a "neutral" rating for the company in a research note on Friday, December 6th. Finally, Leerink Partners restated a "market perform" rating and issued a $31.35 price target (up previously from $29.00) on shares of Patterson Companies in a research note on Wednesday, December 11th. Eleven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $26.57.

Insiders Place Their Bets

In other news, CEO Donald Zurbay sold 1,962 shares of the business's stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $23.08, for a total transaction of $45,282.96. Following the transaction, the chief executive officer now directly owns 222,736 shares in the company, valued at $5,140,746.88. The trade was a 0.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.90% of the stock is owned by company insiders.

About Patterson Companies

Patterson Companies, Inc engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems.